ILLUMINA INC (1ILMN.MI) Stock Fundamental Analysis
BIT:1ILMN - Euronext Milan - US4523271090 - Common Stock - Currency: EUR
Taking everything into account, 1ILMN scores 5 out of 10 in our fundamental rating. 1ILMN was compared to 17 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 1ILMN get a neutral evaluation. Nothing too spectacular is happening here. 1ILMN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1ILMN was profitable.
1ILMN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 1ILMN reported negative net income in multiple years.
Each year in the past 5 years 1ILMN had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -19.39%, 1ILMN is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
1ILMN has a worse Return On Equity (-51.50%) than 87.50% of its industry peers.
The Return On Invested Capital of 1ILMN (10.19%) is better than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.39% | ||
| ROE | -51.5% | ||
| ROIC | 10.19% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of 1ILMN (14.78%) is comparable to the rest of the industry.
1ILMN's Operating Margin has declined in the last couple of years.
1ILMN's Gross Margin of 65.44% is amongst the best of the industry. 1ILMN outperforms 93.75% of its industry peers.
In the last couple of years the Gross Margin of 1ILMN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.78% | ||
| PM (TTM) | N/A | ||
| GM | 65.44% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 1ILMN is destroying value.
Compared to 1 year ago, 1ILMN has about the same amount of shares outstanding.
Compared to 5 years ago, 1ILMN has more shares outstanding
1ILMN has a worse debt/assets ratio than last year.
2.2 Solvency
1ILMN has an Altman-Z score of 3.04. This indicates that 1ILMN is financially healthy and has little risk of bankruptcy at the moment.
1ILMN's Altman-Z score of 3.04 is in line compared to the rest of the industry. 1ILMN outperforms 56.25% of its industry peers.
The Debt to FCF ratio of 1ILMN is 2.81, which is a good value as it means it would take 1ILMN, 2.81 years of fcf income to pay off all of its debts.
1ILMN has a better Debt to FCF ratio (2.81) than 87.50% of its industry peers.
A Debt/Equity ratio of 0.63 indicates that 1ILMN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.63, 1ILMN is in line with its industry, outperforming 43.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 2.81 | ||
| Altman-Z | 3.04 |
ROIC/WACC0.95
WACC10.7%
2.3 Liquidity
A Current Ratio of 1.78 indicates that 1ILMN should not have too much problems paying its short term obligations.
1ILMN has a better Current ratio (1.78) than 75.00% of its industry peers.
A Quick Ratio of 1.42 indicates that 1ILMN should not have too much problems paying its short term obligations.
1ILMN has a Quick ratio of 1.42. This is amongst the best in the industry. 1ILMN outperforms 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
1ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 181.61%, which is quite impressive.
Measured over the past years, 1ILMN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -17.93% on average per year.
1ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -2.93%.
1ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.29% yearly.
EPS 1Y (TTM)181.61%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%514.29%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-1.6%
3.2 Future
Based on estimates for the next years, 1ILMN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.14% on average per year.
Based on estimates for the next years, 1ILMN will show a small growth in Revenue. The Revenue will grow by 4.60% on average per year.
EPS Next Y87.6%
EPS Next 2Y46.05%
EPS Next 3Y33.36%
EPS Next 5Y24.14%
Revenue Next Year0.64%
Revenue Next 2Y2.81%
Revenue Next 3Y4.1%
Revenue Next 5Y4.6%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 34.67 indicates a quite expensive valuation of 1ILMN.
1ILMN's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of 1ILMN to the average of the S&P500 Index (24.21), we can say 1ILMN is valued slightly more expensively.
A Price/Forward Earnings ratio of 18.49 indicates a rather expensive valuation of 1ILMN.
62.50% of the companies in the same industry are more expensive than 1ILMN, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of 1ILMN to the average of the S&P500 Index (20.44), we can say 1ILMN is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.67 | ||
| Fwd PE | 18.49 |
4.2 Price Multiples
62.50% of the companies in the same industry are more expensive than 1ILMN, based on the Enterprise Value to EBITDA ratio.
68.75% of the companies in the same industry are more expensive than 1ILMN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.99 | ||
| EV/EBITDA | 14.14 |
4.3 Compensation for Growth
1ILMN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as 1ILMN's earnings are expected to grow with 33.36% in the coming years.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y46.05%
EPS Next 3Y33.36%
5. Dividend
5.1 Amount
1ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1ILMN (3/20/2025, 7:00:00 PM)
78.71
-18.24 (-18.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.43%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap12.47B
Analysts73.55
Price Target121.39 (54.22%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.56%
Min EPS beat(2)-7.76%
Max EPS beat(2)26.88%
EPS beat(4)2
Avg EPS beat(4)19.35%
Min EPS beat(4)-60.91%
Max EPS beat(4)119.22%
EPS beat(8)6
Avg EPS beat(8)340.29%
EPS beat(12)9
Avg EPS beat(12)230.8%
EPS beat(16)13
Avg EPS beat(16)182.05%
Revenue beat(2)0
Avg Revenue beat(2)-1.04%
Min Revenue beat(2)-1.91%
Max Revenue beat(2)-0.18%
Revenue beat(4)2
Avg Revenue beat(4)-0.25%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.91%
Revenue beat(8)4
Avg Revenue beat(8)-0.46%
Revenue beat(12)4
Avg Revenue beat(12)-1.2%
Revenue beat(16)8
Avg Revenue beat(16)0.55%
PT rev (1m)-22.06%
PT rev (3m)-21.4%
EPS NQ rev (1m)-2.25%
EPS NQ rev (3m)-5.93%
EPS NY rev (1m)-0.37%
EPS NY rev (3m)1.53%
Revenue NQ rev (1m)-0.57%
Revenue NQ rev (3m)-4.36%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-3.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.67 | ||
| Fwd PE | 18.49 | ||
| P/S | 3.08 | ||
| P/FCF | 18.99 | ||
| P/OCF | 16.08 | ||
| P/B | 5.67 | ||
| P/tB | 13.95 | ||
| EV/EBITDA | 14.14 |
EPS(TTM)2.27
EY2.88%
EPS(NY)4.26
Fwd EY5.41%
FCF(TTM)4.15
FCFY5.27%
OCF(TTM)4.89
OCFY6.22%
SpS25.56
BVpS13.88
TBVpS5.64
PEG (NY)0.4
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.39% | ||
| ROE | -51.5% | ||
| ROCE | 13.58% | ||
| ROIC | 10.19% | ||
| ROICexc | 13.7% | ||
| ROICexgc | 22.77% | ||
| OM | 14.78% | ||
| PM (TTM) | N/A | ||
| GM | 65.44% | ||
| FCFM | 16.22% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score6
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 2.81 | ||
| Debt/EBITDA | 1.49 | ||
| Cap/Depr | 36.16% | ||
| Cap/Sales | 2.93% | ||
| Interest Coverage | 7.78 | ||
| Cash Conversion | 83.7% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 3.04 |
F-Score6
WACC10.7%
ROIC/WACC0.95
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)181.61%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%514.29%
EPS Next Y87.6%
EPS Next 2Y46.05%
EPS Next 3Y33.36%
EPS Next 5Y24.14%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-1.6%
Revenue Next Year0.64%
Revenue Next 2Y2.81%
Revenue Next 3Y4.1%
Revenue Next 5Y4.6%
EBIT growth 1Y1504.35%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year37.01%
EBIT Next 3Y19.43%
EBIT Next 5Y16.87%
FCF growth 1Y151.42%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y75.1%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%